S&P Futures
4,133.25 -14.50 (-0.35%) Dow Futures
33,881.00 -81.00 (-0.24%) Nasdaq Futures
12,571.25 -52.75 (-0.42%) Russell 2000 Futures
1,984.40 -9.10 (-0.46%) Crude Oil
73.49 +0.10 (+0.14%) Gold
1,888.80 +12.20 (+0.65%)
Intra-Cellular Therapies, Inc. (ITCI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 49.74 |
| Open | 49.45 |
| Bid | 47.27 x 800 |
| Ask | 50.38 x 1000 |
| Day's Range | 48.29 - 49.81 |
| 52 Week Range | 42.42 - 66.00 |
| Volume | |
| Avg. Volume | 571,926 |
| Market Cap | 4.633B |
| Beta (5Y Monthly) | 1.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.61 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 70.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ITCI
Related Research
- Intra-Cellular Therapies Inc.VNDA: What does Argus have to say about VNDA?VANDA PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.RatingFair ValueEconomic Moat5 days agoArgus Research
- GlobeNewswire
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. PT. The live and archived webcast can be accessed under "Events & Presenta
- Zacks
The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly
United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.
- Zacks
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
